| __timestamp | Apellis Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 504755000 |
| Thursday, January 1, 2015 | 6356782 | 838526000 |
| Friday, January 1, 2016 | 4303743 | 1177697000 |
| Sunday, January 1, 2017 | 10463151 | 1320433000 |
| Monday, January 1, 2018 | 22639184 | 1556200000 |
| Tuesday, January 1, 2019 | 67046483 | 1834800000 |
| Wednesday, January 1, 2020 | 139401000 | 1346000000 |
| Friday, January 1, 2021 | 176771000 | 1824900000 |
| Saturday, January 1, 2022 | 277163000 | 2115900000 |
| Sunday, January 1, 2023 | 500815000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc. have shown distinct approaches in managing their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Regeneron's SG&A expenses have consistently outpaced those of Apellis, peaking at approximately $2.63 billion in 2023. This represents a staggering 420% increase from their 2014 figures. In contrast, Apellis, while starting with a modest $2.9 million in 2014, saw a dramatic rise to $500 million by 2023, marking an exponential growth of over 17,000%.
This divergence highlights Regeneron's established market presence and Apellis's rapid expansion strategy. As these companies continue to innovate, their financial maneuvers offer a window into their strategic priorities and market positioning.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Apellis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Regeneron Pharmaceuticals, Inc.
Pfizer Inc. or Regeneron Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. or Viatris Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and Exelixis, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG Trends and Insights
Regeneron Pharmaceuticals, Inc. or Ligand Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Regeneron Pharmaceuticals, Inc. and Galapagos NV: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Novavax, Inc.
Cost Management Insights: SG&A Expenses for Dr. Reddy's Laboratories Limited and Apellis Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Merus N.V.
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Geron Corporation